A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa | Zendy

Selly Ba | Zendy; Da. Raugi | Zendy; Robert A. Smith | Zendy; Fatima Sall | Zendy; Khadim Faye | Zendy; Stephen E. Hawes | Zendy; Papa Salif Sow | Zendy; Moussa Seydi | Zendy; Geoffrey S. Gottlieb | Zendy; Fatou Traoré | Zendy; Marie Pierre Sy | Zendy; Bintou Diaw | Zendy; Mbaye Ndoye | Zendy; Amadou Bale Diop | Zendy; Marianne Fadam Diome | Zendy; Alassane Niang | Zendy; Jean Jacques Malomar | Zendy; ElHadji Ibrahima Sall | Zendy; Ousseynou Cisse | Zendy; Ibrahima Tito Tamba | Zendy; Jean Philippe Diatta | Zendy; Jacques F. Sambou | Zendy; Raphael Bakhoum | Zendy; Juliette Gomis | Zendy; Noelle A. Benzekri | Zendy; John Lin | Zendy; Nancy B. Kiviat | Zendy; Sally Leong | Zendy; Sara Masoum | Zendy; Vincent H. Wu | Zendy; Carol Gallardo | Zendy; Eleanor Espinosa | Zendy; Ming Chang | Zendy; Bob Coombs | Zendy

Open Access

A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa

Author(s) -

Selly Ba,

Da. Raugi,

Robert A. Smith,

Fatima Sall,

Khadim Faye,

Stephen E. Hawes,

Papa Salif Sow,

Moussa Seydi,

Geoffrey S. Gottlieb,

Fatou Traoré,

Marie Pierre Sy,

Bintou Diaw,

Mbaye Ndoye,

Amadou Bale Diop,

Marianne Fadam Diome,

Alassane Niang,

Jean Jacques Malomar,

ElHadji Ibrahima Sall,

Ousseynou Cisse,

Ibrahima Tito Tamba,

Jean Philippe Diatta,

Jacques F. Sambou,

Raphael Bakhoum,

Juliette Gomis,

Noelle A. Benzekri,

John Lin,

Nancy B. Kiviat,

Sally Leong,

Sara Masoum,

Vincent H. Wu,

Carol Gallardo,

Eleanor Espinosa,

Ming Chang,

Bob Coombs

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy324

Subject(s) - medicine , elvitegravir , emtricitabine , cobicistat , regimen , viral load , adverse effect , tolerability , virology , reverse transcriptase inhibitor , human immunodeficiency virus (hiv) , antiretroviral therapy

Our trial of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate in antiretroviral therapy–naive HIV-2–infected individuals for 48 weeks, in a resource-limited setting, demonstrated favorable immunovirologic outcomes and was well tolerated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research